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background: The aim of the study was to estimate and compare the radiobiological ratio α/β with the heuristic method for a 
cohort of Mexican patients with prostate cancer (pca) who were treated with external radiotherapy (rT) techniques at three 
hospital Institutions in Mexico city. With the Kaplan-Meier technique and the cox proportional hazards model, the biochemi-
cal relapse-free survival (brFs) is determined and characterized for cohorts of Mexican patients with pca who received treat-
ment with external rT. Using these clinical outcomes, the radiobiological parameter α/β is determined using the heuristic 
methodology of pedicini et. al.
Materials and methods: The α/β is calculated from the survival curves for different treatment schemes implemented at 
three distinct hospitals. The pedicini’s techniques allow to determine the parameters α/β, k and N0 when treatments are not 
radiobiologically equivalent, therefore, are built up of a set of curved pairs for the biologically effective dose (BeD) versus the 
ratio α/β, where the ratio is given by the intersection for each pair of curves.
results: six different values of α/β were found: the first α/β = 2.46 Gy, the second α/β = 3.30 Gy, the third for α/β = 3.25 Gy, the 
fourth α/β = 3.24 Gy, the fifth α/β = 3.38 Gy and the last α/β = 4.08 Gy. These values can be explained as follows: a) The brFs of the 
schemes presents a statistical variation; b) The absorbed doses given to the patient present uncertainties on the physical dosim-
etry that are not on the modeling; c) Finally, in the model for the brFs of eq. (3), there are parameters that have to be considered, 
such as: the number of clonogenic tumor cells N0, the overall treatment time (OTT), the kick-off time for tumor repopulation Tk 
and the repopulation doubling time. Therefore, the mean value to α/β for all schemes has an average value of 3.29 (± 0.52) Gy.
conclusions: The value of α/β = 3.29 (± 0.52) Gy is determined from cohorts of Mexican patients with pca treated with external 
radiotherapy using the time-dependent LQ model, which is a higher value with respect to the “dogma” value of α/β 1.5 Gy 
obtained with the LQ model without temporal dependence. Therefore, there is a possibility of optimizing treatments radio-
biologically and improving the results of brFs in Mexican patients with pca treated with external radiotherapy.
Key words: α/β ratio; time-dependent LQ model; biochemical relapse-free survival; brFs; biologically effective dose; BeD; 
prostate cancer, pca
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Introduction
Prostate cancer (PCa) is the second most com-
mon type of cancer in men in the world. Based 
on GLOBOCAN estimates, 1,276,106 new cases 
of PCa were diagnosed worldwide in 2018. In fact, 
there is a great variety of reported incidence rates of 
PCa around the world. In Latin America, 190,385 
new cases of PCa were reported in the same year, 
while in Mexico 25,049 patients with PCa emerged. 
PCa is the second most frequent type of cancer in 
both regions [2].
Consequently, PCa is a major cause of mortality 
among men. Worldwide, this type of cancer was the 
fifth leading cause of death in 2018, with a figure of 
358,989 deaths, while in Mexico that figure reached 
6,915, which was the leading cause of death from 
any type of cancer [2].
Several studies report notable differences in 
the incidence and mortality from PCa amongst 
the different racial groups. For example, there 
is a striking disparity in PCa mortality rate 
among racial groups in the United States, with 
the highest incidence and mortality seen in Af-
rican-American men. Deaths attributable to PCa 
are 2.4 times higher in African-American men 
compared to white men in the United States [3]. 
Additionally, PCa incidence and mortality rates 
are lower among Asian/Pacific Islanders, Ameri-
can Indians/Alaska Natives, and Hispanic men 
when compared to non-Hispanic white men [3]. 
Although more studies are needed to explain the 
causes of these disparities, some of the differences 
observed between racial groups suggest that ge-
netic factors could play an important role in these 
inequalities [4]. However, this issue is extremely 
complex due to its dependence on socioeconomic 
factors, issues that are beyond the scope of this 
research.
The RT is one of the main treatment options for 
PCa. It is well known that there are physical and 
biological factors that influence the response of tis-
sues from treatment. For example, the uncertainty 
of the relative and absolute absorbed dose [5], the 
radiosensitivity, repopulation [1, 6–9], reoxygen-
ation, repair and redistribution [10]. Furthermore, 
PCa has been characterized as a tissue with slow 
repopulation and repair, which is expressed with 
a low value of α/β ~ 1.5 Gy [11–14], an interpre-
tation that seems to be incorrect, since the low 
repopulation does not mean that the temporal de-
pendence in the linear quadratic (LQ) model has to 
be ignored [1]. 
In PCa where a low α/β value has been assumed 
as standard, it is considered that hypofractionation 
schemes can favor cell death and, therefore, a bet-
ter local control of the disease. However, recent re-
search points to the need to consider the time factor 
in the calculation of α/β [1, 6–8, 15]. In these sce-
narios, the tolerances and types of tissues located 
in the treatment area must be considered very care-
fully, due to the risks of developing further toxicity, 
as Ferreira’s studies show [16].
In recent years there has been a rapid increase in 
treatments for PCa with hypofractionated external 
RT. Even though, there are results in several coun-
tries regarding the radiobiological equivalence of 
PCa treatment schemes (hypo vs. standard), it is 
convenient to determinate and verify the values 
of the radiobiological parameters for the Mexican 
male population. With the aim in mind of perform-
ing a radiobiological optimization in such treat-
ments for the Mexican population. 
The foregoing is of enormous importance, given 
that these studies are not available in our country, 
Mexico. As mentioned above, there are notable dif-
ferences in the incidence and mortality from PCa 
between ethnic groups, the causes of which are not 
yet known and deserve further explanation. It is 
very important to create a national cancer registry 
with reliable data on incidence rates, tumor type 
and location, mortality and morbidity allowing us 
to carry out radiobiological modeling in our Mexi-
can population [17, 18]. 
To summarize, the aim of this work is to es-
timate and compare the radiobiological ratio 
α/β for Mexican patients with PCa who were 
treated with external RT techniques. The test-
ing took place in three separate hospital institu-
tions located in Mexico City. The RT techniques 
used in these patients were three-dimensional 
conformal radiation therapy (3D-CRT), intensi-
ty-modulated radiation therapy (IMRT) and ste-
reotactic body radiation therapy (SBRT) [19]. The 
biochemical relapse-free survival (bRFS) values 
obtained in the study are taken as a reference 
to perform a radiobiological optimization [19]. 
These values are also used to determine the α/β 
for the Mexican population by which the heuristic 
Pedicini’s method is used [20].
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Materials and methods 
The bRFS rates are obtained and characterized 
with the Kaplan-Meier technique for a cohort of 
Mexican patients (nTotal = 595) with PCa who re-
ceived treatment with external radiotherapy [19], 
see Table 1. This research confirms that the rates 
of bRFS are statistically equivalent within the co-
hort of Mexican patients with respect to the treat-
ments. In other words, the treatments reported in 
this work are radiobiologically equivalent. By us-
ing these clinical outcomes, a set of radiobiological 
parameters α/β for a Mexican population cohort is 
determined.
It is worth mentioning that the BED and the 
equivalent dose (EQ2) are calculated and reported 
in Table 1 using the α/β =1.4 given for a Caucasian 
population [11].
On the other hand, the radiobiological models 
based on the LQ equation have been widely used 
over the years to describe the surviving fraction S 
after receiving an absorbed dose D [20, 21].
This S is expressed as:
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where E is the biologically effective yield of lethal 
damage per cell; moreover, when E is corrected for 
repopulation effect, then it is written as:
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here the radiobiological parameters α and β spec-
ify the radiosensitivity of the tumor, while the total 
absorbed dose delivered is given D = n x d, where n 
is the number of treatment fractions. T represents 
overall treatment time (OTT), Tk is the kick-off 
time for tumor repopulation and k = ln2/αTd quan-
tifies the rate of tumor repopulation [22]; Td being 
the repopulation doubling time. It is to note that, 
unfortunately, Pedicini defines the γ parameter that 
corresponds to the k parameter of our Eq. (2) incor-
rectly, as γ = ln2/Td, see Kahn’s Eq. (20.13) [20, 23].
The bRFS for outcomes of radiation treatment is 
calculated from S of Eq. (1), assuming the Poisson 
distribution as [20]:
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where the bRFS for a treatment scheme defined 
by: d, D and T, is modeled with the K-M technique, 
see Table 1; and, N0 is the number of clonogenic 
cells in the tumor volume, where, unfortunately, 
some studies do not take care to verify the values of 
this parameter [11, 20].
On the other hand, the BED is derived directly 
from the LQ for the cell survival, where the BED is 
used to calculate and compare treatment schemes 
that are equally biologically effective [23].
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here d is the absorbed dose per fraction and n is 
the number of fractions reported in Table 1.
Thus, due to the fact that our treatment schemes 
are radiobiologically equivalent [19], the α/β is 
determined for the different treatment schemes 
with the BED calculated with Eq. (4) under the 
former hypothesis and the assumption that the 
doubling time Td = 50 days and an accelerated 
repopulation time Tk = 30 days, which correspond 
to k = 0.1 Gy/day recommended by Khan [23]. It 
table 1. The biochemical relapse-free survival (brFs) rates by institution, technique, and treatment scheme from prostate 
cancer (pca) Mexican cohort and biologically effective dose (BeD) and equivalent dose (eQ2) calculated with α/β = 1.4 Gy
Hospital No. patients Technique Dose fx [Gy] Total dose [Gy] EQ2 [Gy] BED [Gy] bRFS rate
IMss
93 3D-crT 1.8 70–79 62–70 157–177 94.60%
80 3D-crT 2.66 66 77 190 91.30%
121 sBrT 7 35 90 214 95.90%
129 sBrT 7.25 36 92 228 89.10%
IsssTe 57 3D-crT 1.8–2.0 60–74 58–66 143–165 87.70%
hGM 115 IMrT 1.8 76–79 67–70 169–177 88.70%
Global 595 91.40%
3D-crT — three-dimensional conformal radiation therapy; sBrT — stereotactic body radiation therapy; IMrT — intensity-modulated radiation therapy
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should be noted that to uniquely determine the 
parameter k, it is necessary to calculate a, which 
we have determined from our data as α = 0.130 
(± 0.010) Gy.
In fact, we tried to use the values Td = 5.1 days 
and Tk = 30 days used by Pedicini; however, it gives 
us a value of k = 1.20 Gy/day, which is not consistent 
with the clinical recommendations of Khan [23]. 
On the other hand, if we take the Vogelius value of 
0.31 Gy/day [6], it would correspond to Td and Tk of 
19.4 days and 30 days, respectively, except for the α 
value that is a free parameter. Because of this, which 
we have determined as the α = 0.130 (± 0.010) Gy; 
robust criteria or techniques are required to univo-
cally determine the Td and Tk times consistent with 
the clinical data of the survival curves. 
This heuristic technique consists in obtaining 
the α/β as the intersection point on the curves BED 
versus α/β plotted for two treatments that are not 
necessarily radiobiologically equivalent (that is, 
they may have statistically different bRFS). In ad-
dition, this technique is used for considering heu-
ristically values of Td, Tk and N0 that are logically 
consistent with the observed clinical results. This 
is unlike other models that estimate inconsistent 
N0 parameters and that show a biased time depen-
dence analysys [11]. 
To summarize and reiterate with pedagogi-
cal purposes: the treatment schemes published 
by Adame et al. are radiobiologically equivalent 
[19], the α/β’s are determined using the reported 
bRFS’s and calculated BED’s. with Eq. (4). There-
fore, the α/β ratios are obtained from the BED 
curves as a function of α/β and k, where their 
values correspond to the point of intersection of 
the curves [14].
results
Figure 1 shows 6 different curves for the BED 
values as a function of α/β’s for Td = 50 days (k = 0.1 
Gy/days) y Tk = 30 days corresponding to the exter-
nal RT treatment schemes used, where six points of 
intersection are found.
To increase the understanding and precision of 
the α/β values found, the pairs of curves related 
to the observed intersection points are presented 
individually below:
• the first point of intersection has a value 
α/β = 2.46 Gy, see Figure 2, and is associated 
with the IMSS-SBRT-HS vs. IMSS-3D-HS treat-
ment schemes;
• the second value of α/β is better observed in 



















Figure 1. Biologically effective dose (BeD) vs. α/β ratio for three cohorts of Mexican prostate cancer (pca) patients treated 
with three external radiotherapy techniques: stereotactic body radiation therapy (sBrT), three-dimensional conformal 
radiation therapy (3D-crT) and intensity-modulated radiation therapy (IMrT) at three public Mexican institutions: IMss, 
IsssTe and hG. ss — standard scheme; hs — hypofractionated scheme
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to the pair of treatment schemes IMSS-3D-HS 
vs HGM-IMRT-SS;
• next, the Figure 4 shows the pair of treatments 
arms IMSS-SBRT-HS2 vs. HGM-IMRT-SS, 
where there is a third point for α/β 3.25 Gy;
• in addition to the above, a fourth and a fifth 
value of α/β is found at the intersection of 3.24 
Gy for the IMSS-SBRT-HS vs ISSSTE-3D-SS and 
3.38 Gy for the IMSS-3D-HS vs IMSS-SBRT-HS2 
schedules respectively (Fig. 5).
• finally, an α/β is present in Figure 6, with a value 
slightly higher than the rest (4.08 Gy), for the 
IMSS-SBRT-HS2 vs ISSSTE-3D-SS treatment 
arms.
The different values of α/β can be explained as 
follows: a) the bRFS’s do meet the H0 of being equal, 
but have a statistical variability associated with the 
significance level alpha, b) the absorbed dose D 
delivered to the patient presents an expanded un-


















Where these curves intersect shows the best value for α/β
Td = 50
days
















Where these curves intersect shows the best value for α/β
Td = 50  days
Figure 3. IMss-3D-hs vs. hGM-IMrT-ss treatment schemes, α/β = 3.30 Gy
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α/β for all the schemes have an average value of 
α/β = 3.29 (± 0.52) Gy, d) this interval value is com-
patible and consistent with the results determined 
by using the time-dependent LQ models in previ-
ous publications [6, 7, 15]. 
However, in Eq. (2) additional factors are tak-
en into account [20]: N, T, Tk and Td; which are 
presented as a function of the risk group. In fact, 
the section: Biologically Effective Dose Model in 
[20] explains the importance of the temporal pa-
rameters; where they are manifested as a loss of 
tumor control through repopulation, which mani-
fests itself as an underestimation of the α/β ratio [1, 
6].To emphasize this, remember that the medical 
physicist employs these parameters in the clinical 


















Where these curves intersect shows the best value for α/β
Td = 50  days




















Where these curves intersect shows the best value for α/β
Td = 50   days
Figure 5. α/β’s for the IMss-sBrT-hs vs. IsssTe-3D-ss and IMss-3D-hs vs. IMss-sBrT-hs2 treatment schemes, respectively
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Discussion
It is important to note that for each fractionation 
scheme, the BED and EQ2 on Table 1 are calculated 
using clinical protocols that assume a relationship 
of 1.4 Gy [1]. But the calculation of the BED and 
EQ2 in Table 2 is prepared with the α/β = 3.29 Gy 
determined for the cohort of Mexican PCa patients.
Analyzing the values of EQ2 obtained with 
the α/β = 3.29 Gy, it is observed that these val-
ues decreased by up to 20% for the hypofractioned 
schemes with respect to those shown in Table 1. 
Specifically, this verifies that the value α/β = 3.29 Gy 
is logically consistent with the EQ2 values. In fact, 
since the new values for EQ2’s calculated consider 
the temporal dependence are in order of 72–76 Gy, 
it means that these values are coherent with those 
of conventional treatment schemes. Therefore, from 
the point of view of radiobiological optimization, 
the α/β = 3.29 (± 0.52) Gy is what best fits the 
survival curves of the Mexican population for the 
treatment of PCa.
It seems that there is a great variation in the ex-
tremes of the α/β ratio for the schemes studied in 
this work, but different studies have found similar 
ratios [6, 15, 20]. However, as mentioned previ-
ously, the temporal dependence of the LQ model 
should not be omitted since it implies the risk of 
making biased estimates of the α/β ratio.
Another important point is to consider the effect 
of uncertainty in the total dose administered to 














Where these curves intersect shows the best value for α/β
Td = 50   days
Figure 6. α/β = 4.08 Gy for the IMss-sBrT-hs2 vs. IsssTe-3D-ss for both schedules
table 2. Biologically effective doses (BeD) and equivalent doses (eQ2) of the different treatments using α/β = 1.4 Gy and α/β = 
3.29 Gy determined for a Mexican cohort of prostate cancer (pca) population
Technique Dose fx [Gy] Fractions [n]
EQ2 [Gy] α/β Gy
k = 0.1 Gy/day 
bED [Gy] 
α/β Gy 
k = 0.1 Gy/day 
EQ2 [Gy]
α/β Gy 
k = 0.1 Gy/day
bED [Gy] α/β Gy 
k = 0.1 Gy/day
3D-crT 1.8 39–44 62–70 157–177 64–72 105–118
3D-crT 2.66 25 77 190 73 118
sBrT 7 5 90 214 72 113
sBrT 7.25 5 92 228 76 120
3D-crT 1.8–2.0 30–41 58–66 143–165 58–67 94–110
IMrT 1.8 42–44 67–70 169–177 69–72 113–118
3D-crT — three-dimensional conformal radiation therapy; sBrT — stereotactic body radiation therapy; IMrT — intensity-modulated radiation therapy
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which has not been addressed in detail in the mod-
ern literature for these type of treatments for PCa 
[20]. To demonstrate this with a simple exercise, 
Figures 7 and 8 were performed to exemplify what 
could happen for the α/β values if there was an 
uncertainty in the absorbed dose administered to 
the patients. For such an example, ± 2% combined 
uncertainty (uc) bars and curves with an uc  of ± 3% 
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Figure 8. uc introduced for equivalent dose (eQ2) vs. the α/β ratio for IMss-3D-hs scheme. Doses different by ±2%, ±3% and 
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Figure 7. Uncertainties introduced for equvalent dose (eQ2) vs. the α/β ratio for the IMss-sBrT-hs scheme. eQ2 with different 
uc ± 2%, ± 3% and ± 5% are calculated to generate the curves
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In the Figure 7 it is shown with an uc in the total 
absorbed dose administered to the patient of ± 5%, 
it could cause a great variation in the radiobio-
logical parameter α/β changing its value for this 
example from 2.9 Gy to 4.1 Gy, respectively. On the 
other hand, if you had a deviation of ±3% in the to-
tal absorbed dose, you would have an approximate 
α/β of 3.1 Gy to 3.8 Gy, respectively.
In the same way, in Figure 8 errors were induced 
in the total absorbed dose and concentrating on 
the corresponding uc = ± 3%, we can see that the 
alpha/beta ratio increases from 2.1 to 5.2 Gy.
Figures 7 and 8 are simply an illustration of the 
wide variation that can occur in the results due to 
possible random uc [5].
conclusions
This study confirms that the main disadvantage 
of the treatment of PCa with standard schemes of 
radiotherapy is the duration of the treatment. This 
means that the possibility of reducing the treatment 
time, delivering higher absorbed doses per fraction, 
has benefits from an economic and administrative 
point of view. Improving and optimizing the use of 
technical and human resources allows the patient 
to finish his treatment in a shorter period. The cost 
of treatment is lower for the institution and the 
patient. This will increase access to treatment for 
more patients.
From Figures 1–6 it is concluded that the aver-
age value for α/β = 3.29 (± 0.52) Gy for a cohort of 
Mexican patients with PCa treated with external 
radiotherapy.
Using the time-dependent LQ model it is ob-
served that the value α/β = 3.29 (± 0.52)  is higher 
than 1.5 Gy calculated with basic LQ models (with-
out temporal dependence); where  our interval 
value α/β is compatible and consistent with the 
results determined with the time-dependent LQ 
models on previous publications [6, 7]. It is worth 
mentioning that our α/β is calculated considering 
k = 0.1 Gy/day, with Td = 50 days, Tk = 30 days and 
α = 0.130 (± 0.010) Gy. 
The most important conclusion is that once the 
relationship optimized α/β ratio of 3.29 Gy was 
validated for the Mexican population, it could be 
used as an accurate and precise radiobiological 
parameter for the design of external RT fraction-
ation schemes to optimize treatment of PCa in 
the Mexican population and improve their bRFS 
values.
Finally, it is necessary to continue with an exhaus-
tive study of the LQ model as a function of time with 
the data of the Mexican patients with PCa.
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